- /
- Supported exchanges
- / US
- / ADVM.NASDAQ
Adverum Biotechnologies Inc (ADVM NASDAQ) stock market data APIs
Adverum Biotechnologies Inc Financial Data Overview
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Adverum Biotechnologies Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Adverum Biotechnologies Inc data using free add-ons & libraries
Get Adverum Biotechnologies Inc Fundamental Data
Adverum Biotechnologies Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -186 224 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -1.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adverum Biotechnologies Inc News
New
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early October. The 50-day moving average is a short-term indicator, ...
March Biosciences Designates Dr. Gurpreet Ratra as Chief Business Officer
By Karen Roman March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and ge...
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
Adverum Biotechnologies, Inc. Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a Liquidation REDWOOD CITY, Calif., Dec. 01, 2025 ...
Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.